Total Payments
$1,722
2024 Payments
$624.41
Companies
20
Transactions
58
Medicare Patients
3,370
Medicare Billing
$631,890
Payment Breakdown by Category
Food & Beverage$1,619 (94.0%)
Education$103.07 (6.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,619 | 56 | 94.0% |
| Education | $103.07 | 2 | 6.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $303.72 | 10 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $281.92 | 10 | $0 (2024) |
| NXSTAGE MEDICAL, INC. | $233.64 | 2 | $0 (2024) |
| BAXTER HEALTHCARE | $189.52 | 3 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $148.07 | 2 | $0 (2023) |
| Fresenius USA Marketing, Inc. | $121.28 | 5 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $56.51 | 3 | $0 (2024) |
| Amgen Inc. | $47.19 | 2 | $0 (2024) |
| Vifor Pharma, Inc. | $44.90 | 3 | $0 (2024) |
| Relypsa, Inc. | $42.75 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $624.41 | 18 | NXSTAGE MEDICAL, INC. ($220.76) |
| 2023 | $208.50 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($148.07) |
| 2022 | $16.31 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($16.31) |
| 2021 | $17.02 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($17.02) |
| 2020 | $84.45 | 5 | AstraZeneca Pharmaceuticals LP ($30.81) |
| 2019 | $245.82 | 9 | Mallinckrodt Enterprises LLC ($119.64) |
| 2018 | $310.20 | 10 | BAXTER HEALTHCARE ($124.99) |
| 2017 | $215.41 | 10 | Mallinckrodt LLC ($109.33) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: Phosphate binder for ESRD | ||||||
| 11/11/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Hyperkalemia | ||||||
| 11/07/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Hyperkalemia | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $14.03 | General |
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/28/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $12.68 | General |
| 08/16/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/14/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Inflammation | ||||||
| 08/07/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug), OPTIFLUX | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: Cardio-renal | ||||||
| 06/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $121.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/09/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $19.64 | General |
| 05/09/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 04/04/2024 | NXSTAGE MEDICAL, INC. | NXSTAGE SYSTEM ONE (Device) | Food and Beverage | In-kind items and services | $220.76 | General |
| Category: Nephrology | ||||||
| 02/29/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $20.21 | General |
| 02/16/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/18/2024 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $23.44 | General |
| 01/08/2024 | Vifor Pharma, Inc. | — | Food and Beverage | In-kind items and services | $15.92 | General |
| 11/09/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 08/17/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: DIABETES | ||||||
| 05/02/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: NEPHROLOGY | ||||||
| 04/26/2023 | Fresenius USA Marketing, Inc. | Velphoro (Drug), KORSUVA | Food and Beverage | In-kind items and services | $38.22 | General |
| Category: Phosphate binder for ESRD | ||||||
| 09/07/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: Cardio-renal | ||||||
| 06/01/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kyleena (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: Women's Health | ||||||
| 10/07/2020 | Bard Peripheral Vascular, Inc. | LUTONIX (Device) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: BD Interventional - Peripheral Intervention | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 720 | 1,192 | $435,877 | $119,650 |
| 2022 | 13 | 844 | 1,483 | $569,645 | $165,841 |
| 2021 | 13 | 882 | 1,605 | $449,507 | $173,730 |
| 2020 | 12 | 924 | 1,695 | $457,645 | $172,669 |
Total Patients
3,370
Total Services
5,975
Medicare Billing
$631,890
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 61 | 112 | $99,256 | $30,332 | 30.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 167 | 405 | $78,722 | $24,723 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 213 | 296 | $95,379 | $17,123 | 18.0% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 18 | 79 | $58,132 | $17,063 | 29.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 71 | 78 | $25,709 | $7,727 | 30.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 47 | $20,891 | $6,246 | 29.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 50 | 68 | $19,650 | $6,128 | 31.2% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 21 | 25 | $18,463 | $5,273 | 28.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 19 | 27 | $4,853 | $1,457 | 30.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 28 | $6,382 | $1,436 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $4,973 | $1,108 | 22.3% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 15 | 16 | $3,468 | $1,031 | 29.7% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 81 | 182 | $162,782 | $50,872 | 31.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 176 | 504 | $88,060 | $28,031 | 31.8% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 77 | 109 | $80,437 | $25,223 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 218 | 304 | $97,542 | $18,766 | 19.2% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 19 | 57 | $41,960 | $13,105 | 31.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 78 | 84 | $28,212 | $8,866 | 31.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 38 | 39 | $19,014 | $6,036 | 31.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 37 | 46 | $11,584 | $3,619 | 31.2% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 31 | 58 | $10,516 | $3,262 | 31.0% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2022 | 17 | 18 | $9,144 | $2,857 | 31.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $9,350 | $2,668 | 28.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 38 | 39 | $9,048 | $1,904 | 21.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 12 | 21 | $1,996 | $633.72 | 31.7% |
About Dr. Daniel Young, MD
Dr. Daniel Young, MD is a Nephrology healthcare provider based in Fenton, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1184742520.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Young, MD has received a total of $1,722 in payments from pharmaceutical and medical device companies, with $624.41 received in 2024. These payments were reported across 58 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($1,619).
As a Medicare-enrolled provider, Young has provided services to 3,370 Medicare beneficiaries, totaling 5,975 services with total Medicare billing of $631,890. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Internal Medicine, Hospitalist
- Location Fenton, MO
- Active Since 03/26/2007
- Last Updated 12/01/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1184742520
Products in Payments
- ACTHAR (Biological) $326.34
- NXSTAGE SYSTEM ONE (Device) $220.76
- FARXIGA (Drug) $155.83
- JARDIANCE (Drug) $148.07
- LOKELMA (Drug) $126.09
- Renal - Non Product Related (Biological) $124.99
- Velphoro (Drug) $97.84
- Veltassa (Drug) $71.73
- Renal - Chronic (Device) $44.12
- JYNARQUE (Drug) $42.21
- Kerendia (Drug) $39.49
- Rituxan (Biological) $33.86
- KRYSTEXXA (Biological) $27.02
- TAVNEOS (Drug) $26.82
- Palindrome (Device) $22.65
- Renal - Amia (Device) $20.41
- Parsabiv (Biological) $20.37
- Cook Medical Angioplasty (Device) $17.62
- Kyleena (Drug) $17.02
- LUTONIX (Device) $17.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.